Quinolone antibiotics: A potential adjunct to intravesical chemotherapy for bladder cancer

被引:51
|
作者
Kamat, AM [1 ]
DeHaven, JI [1 ]
Lamm, DL [1 ]
机构
[1] W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Urol, Morgantown, WV 26506 USA
关键词
D O I
10.1016/S0090-4295(99)00064-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Despite complete transurethral resection of superficial bladder tumors, the recurrence rate averages 88% at 15 years. Intravesical chemotherapy decreases the recurrence rate, particularly if given immediately after tumor resection. Anticancer drugs such as doxorubicin target topoisomerase II as do the quinolone antibiotics. We evaluated two fluoroquinolones independently and in combination with doxorubicin for cytotoxic effects against bladder cancer cells in vitro. Methods. Three human transitional carcinoma cell lines, T24 (grade I), HTB9 (grade II), and TccSup (grade IV), were exposed to either ciprofloxacin or ofloxacin in concentrations ranging from 0 (control) to 1000 mu g/mL for 24, 48, and 96 hours. In a separate experiment, a 30% cytotoxic dose (IC30) of doxorubicin was applied to the cell cultures for 1 hour and washed off, followed by exposure to ciprofloxacin or ofloxacin for 48 and 96 hours. Cytotoxicity was evaluated using the MTT colorimetric assay. Results. At 96 hours, significant cytotoxicity (P <0.05) for ciprofloxacin was seen starting at 12.5 mu g/mL (HTB9, TccSup) and 50 mu g/mL (T24) and for ofloxacin at 12.5 mu g/mL (HTB9) and 50 mu g/mL (TccSup, T24). Maximum cytotoxicity with ciprofloxacin was 95.4 +/- 0.4% (HTB9, 400 mu g/mL] and with ofloxacin was 95.2 +/- 0.3% (HTB9, 800 mu g/mL). Exposure to doxorubicin (IC30 1 hour) resulted in cell kill rates of 30.9 +/- 5.2% (T24), 50.7 +/- 2.7% (HTB9), and 25.4 +/- 10.6% (TccSup). The addition of as little as 25 mu g/mL of ciprofloxacin increased kill rates to 78.5 +/- 1.2% (T24), 61.2 +/- 1.6% (HTB9), and 74.2 +/- 2.4% (TccSup); Pt 0.05 relative to doxorubicin alone. Similarly, 50 mu g/mL of ofloxacin significantly increased kill rates to 81.8 +/- 1.6% (T24), 63.3 +/- 2.5% (HTB9), and 67.8 +/- 2.0% (TccSup). Both drugs showed even greater synergism at higher concentrations. Conclusions. Ciprofloxacin and ofloxacin exhibit significant time- and dose-dependent cytotoxicity against transitional carcinoma cells and significantly enhance the cytotoxicity of doxorubicin. These effects occur at concentrations achievable in the urine of patients after oral administration. This suggests that quinolone antibiotics might be useful as an adjunct to intravesical chemotherapy and might reduce seeding of cancer cells after transurethral resection of bladder tumors. UROLOGY 54: 56-61, 1999. (C) 1999, Elsevier Science Inc.
引用
收藏
页码:56 / 61
页数:6
相关论文
共 50 条
  • [1] Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer
    Owusu, Richmond A.
    Abern, Michael R.
    Inman, Brant A.
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [2] Intravesical chemotherapy and bladder cancer
    Wallerand, H.
    PROGRES EN UROLOGIE, 2009, 19 (12): : 868 - 871
  • [3] Intravesical chemotherapy for superficial bladder cancer
    Witjes, J. Alfred
    Debruyne, Frans M. J.
    NATURE CLINICAL PRACTICE UROLOGY, 2004, 1 (02): : 56 - 57
  • [4] Nanomedicines for Intravesical Chemotherapy in Bladder Cancer
    Guo, Hui
    Hou, Yuchuan
    Ding, Jianxun
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (04) : 371 - 373
  • [5] Intravesical chemotherapy for superficial bladder cancer
    J Alfred Witjes
    Frans MJ Debruyne
    Nature Clinical Practice Urology, 2004, 1 (2): : 56 - 57
  • [6] Intravesical chemotherapy for superficial bladder cancer
    Witjes, JA
    Debruyne, FMJ
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (04): : A56 - A57
  • [7] INTRAVESICAL CHEMOTHERAPY IN URINARY-BLADDER CANCER
    EDSMYR, F
    ANDERSON, L
    ESPOSTI, PL
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1983, 11 : S67 - S68
  • [8] Treatment of superficial bladder cancer with intravesical chemotherapy
    Badalament, RA
    Farah, RN
    SEMINARS IN SURGICAL ONCOLOGY, 1997, 13 (05): : 335 - 341
  • [9] Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer
    Joice, Gregory A.
    Bivalacqua, Trinity J.
    Kates, Max
    NATURE REVIEWS UROLOGY, 2019, 16 (10) : 599 - 612
  • [10] Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer
    Gregory A. Joice
    Trinity J. Bivalacqua
    Max Kates
    Nature Reviews Urology, 2019, 16 : 599 - 612